SEC Tracker
Get the app

Nautilus Biotechnology NAUT

Nautilus Biotechnology Q1 FY25: net loss $16.6M; diluted EPS −$0.13

Form
10-Q
Filed
Period
Importance
Notable

Key figures from this report

These are the numbers Nautilus Biotechnology reported for Q1 FY25, the quarter ended Mar 31, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Net income−$16.6MAgainst −$18.7M in Q1 FY2410-Q income statement, on EDGAR
  2. Diluted EPS−$0.13Against −$0.15 in Q1 FY2410-Q income statement, on EDGAR
  3. Cash and cash equivalents$33.2M+29% from $25.7M in Q1 FY24Cash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  4. Cash from operations−$13.9MAgainst −$16.3M in Q1 FY2410-Q cash flow statement, on EDGAR

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Nautilus Biotechnology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3826 and related industry codes: the same peer list as the financial tables.

  1. Sypris Solutions SYPR public float $28M, Jun 29, 2025
  2. ClearSign Technologies CLIR public float $28M, Jun 30, 2025
  3. Data I/O DAIO public float $27M, Jun 30, 2025
  4. Optex Systems Holdings OPXS public float $26M, Mar 30, 2025, over 18 months old
  5. Birchtech BCHT public float $51M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.